Financings Of The Fortnight Ponders The Meaning Of The Best Year For Biotech IPOs Since 2007
This article was originally published in The Pink Sheet Daily
Plus news on recent financings by Regulus, Aragon, Antabio and Asceneuron.
You may also be interested in...
The San Diego biotech’s Series D round will support continued development of a drug that Medivation claims was included in the same license that covered the recently approved prostate cancer drug Xtandi.
Higher valuations, better quality companies, improved aftermarket performance and a broadening investor pool are all conspiring to advance the state of biotech IPOs. But VCs continue to see little step-up at IPO.
The efficiency program outlined by the German pharma in February will mean elimination of 500 Merck Serono staff in Switzerland, with another 750 employees being redeployed to Germany, China or the U.S.